Novartis gets FTC approval for GSK deal, with caveat; Merck puts pediatric HIV med in patent pool;

@FiercePharma: Baxter U.S. Selects Bannockburn, Ill., Facility as Location for Baxalta Global Headquarters. Release | Follow @FiercePharma

@CarlyHFierce: ICYMI: Canadian paper backpedals from Gardasil side effects story. Report | Follow @CarlyHFierce

> Novartis ($NVS) has agreed to sell off BRAF and MEK assets it has under development for fighting melanoma to Array BioPharma in order to win FTC approval of its $16 billion deal to buy GlaxoSmithKline ($GSK) oncology drugs. Story

> Merck ($MRK) has worked a deal with the Medicines Patent Pool to grant a license to any drugmaker that wants to make low-cost version of its pediatric HIV med raltegravir in any of 92 low- and middle-income countries. Report

> TWI will take back rights from Teva ($TEVA) to several generic drugs and assemble a U.S. team to sell them in the U.S. Release

> Italian regulators have approved Celgene's cancer drug Abraxane as a first-line treatment, in combo with gemcitabine, of adult patients with metastatic pancreatic cancer. Release

Medical Device News

@FierceMedDev: ICYMI yesterday: Medtronic works to boost neuromodulation with bladder control startup acquisition. Article | Follow @FierceMedDev

@VarunSaxena2: The 10 largest med tech M&A deals announced in 2014. Feature | Follow @VarunSaxena2

@EmilyWFierce: Turning to Twitter, MD Anderson doc launches campaign against cancer drug prices. Story | Follow @EmilyWFierce

> J&J adds $420M to legal stockpile to resolve all-metal hip implant suits. News

> Biotronik says its investigational nitinol stent performed well in clinical trials. Report

Biotech News

@FierceBiotech: Novartis bags a surprise approval for the blood cancer-treating panobinostat. Article | Follow @FierceBiotech

@JohnCFierce: Top story yesterday: UPDATED: Bristol-Myers bags IDO immunotherapy in $1.25B buyout of fledgling Flexus. Article | Follow @JohnCFierce

@DamianFierce: MD Anderson has a Houston Rockets sponsorship called "Moon Shot of the Night," because why not. Video | Follow @DamianFierce

> Alkermes dumps its pain drug after a Phase I disappointment. Story

> Cebix hangs it up after raising $50M for diabetes drug. Article

> Shire's shopping spree continues with a buyout of rare disease biotech. Report

Biotech Research News

> MD Anderson team explores a combination approach against cancer metastasis. More

> Study: New antibody blocks dengue virus. Item

> UC San Diego group zeroes in on breaking a link between obesity and diabetes. Story

> Langer team offers up a hydrogel drug delivery vehicle at MIT. Report

> CRISPR project points to a new approach on Duchenne muscular dystrophy. Article

Pharma Manufacturing News

> Sun Pharma recalls epilepsy drug as dissolution woes continue. News

> Mylan bags rights to distribute Gilead's Sovaldi in India. Item

> Lupin plant hit with Form 483 but continues to rack up approvals. Report

> McKesson outed as company behind 340,000-sq-ft distribution hub in Iowa. Story

> India turns to small manufacturers for state-run generic supply biz. Article

And Finally... The feds have wrapped probe into allegations of foreign bribery against Eli Lilly ($LLY) that date back two decades. Story

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.